



CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)

(in millions)	2024				2025				2026	
	Mar 31	Jun 30	Sep 30	Dec 31	Mar 31	Jun 30	Sep 30	Dec 31	Mar 31	Jun 30
Assets										
Cash, cash equivalents and marketable debt securities	\$ 4,718	\$ 2,772	\$ 5,037	\$ 9,991	\$ 7,926	\$ 7,126	\$ 9,354	\$ 10,605	\$ 8,625	\$ 3,179
Accounts receivable, net	4,669	4,663	4,587	4,420	4,388	4,781	5,095	4,913	4,741	5,055
Inventories	3,363	3,388	3,435	3,589	3,778	3,913	4,387	4,368	4,339	4,298
Property, plant and equipment, net	5,321	5,346	5,391	5,414	5,421	5,459	5,500	5,606	5,638	5,833
Intangible assets, net	23,428	22,832	20,546	19,948	19,355	18,566	17,970	16,978	16,382	14,032
Goodwill	8,314	8,314	8,314	8,314	8,314	8,314	8,314	8,314	8,314	8,314
Other assets	6,479	6,265	7,215	7,319	7,253	7,563	7,914	8,239	8,239	8,652
Total assets	<u>\$ 56,292</u>	<u>\$ 53,579</u>	<u>\$ 54,525</u>	<u>\$ 58,995</u>	<u>\$ 56,434</u>	<u>\$ 55,721</u>	<u>\$ 58,533</u>	<u>\$ 59,023</u>	<u>\$ 56,278</u>	<u>\$ 49,362</u>
Liabilities and Stockholders' Equity										
Current liabilities	\$ 13,015	\$ 10,781	\$ 11,725	\$ 12,004	\$ 12,344	\$ 11,189	\$ 12,298	\$ 11,813	\$ 9,476	\$ 11,020
Long-term liabilities	25,822	24,602	24,409	27,744	25,012	24,942	24,780	24,592	23,371	26,598
Stockholders' equity	17,455	18,197	18,390	19,246	19,078	19,590	21,456	22,618	23,431	11,744
Total liabilities and stockholders' equity	<u>\$ 56,292</u>	<u>\$ 53,579</u>	<u>\$ 54,525</u>	<u>\$ 58,995</u>	<u>\$ 56,434</u>	<u>\$ 55,721</u>	<u>\$ 58,533</u>	<u>\$ 59,023</u>	<u>\$ 56,278</u>	<u>\$ 49,362</u>

Certain amounts and percentages may not sum or recalculate due to rounding.



CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - GAAP
(unaudited)

	2024					2025					2026	
(in millions, except percentages and per share amounts)	Q1	Q2	Q3	Q4	FY24	Q1	Q2	Q3	Q4	FY25	Q1	Q2
Revenues:												
Product sales	\$ 6,647	\$ 6,912	\$ 7,515	\$ 7,536	\$ 28,610	\$ 6,613	\$ 7,054	\$ 7,345	\$ 7,903	\$ 28,915	\$ 6,946	\$ 7,627
Royalty, contract and other revenues	39	41	30	33	144	54	27	424	22	527	14	176
Total revenues	6,686	6,954	7,545	7,569	28,754	6,667	7,082	7,769	7,925	29,443	6,960	7,803
Costs and expenses:												
Cost of goods sold	1,552	1,544	1,574	1,581	6,251	1,540	1,501	1,569	1,623	6,234	1,445	1,579
Research and development expenses	1,520	1,351	1,395	1,641	5,907	1,379	1,491	1,346	1,584	5,799	1,372	1,764
Acquired in-process research and development expenses	4,131	38	505	(11)	4,663	253	61	170	539	1,024	107	11,183
In-process research and development impairment	2,430	—	1,750	—	4,180	—	190	—	400	590	—	1,750
Selling, general and administrative expenses	1,375	1,377	1,433	1,906	6,091	1,258	1,365	1,357	1,794	5,774	1,451	1,921
Total costs and expenses	11,008	4,309	6,657	5,118	27,092	4,430	4,608	4,442	5,940	19,421	4,374	18,197
Operating (loss) income	(4,322)	2,644	888	2,451	1,662	2,237	2,474	3,327	1,984	10,022	2,586	(10,394)
Interest expense	254	237	238	248	977	260	254	256	255	1,024	240	247
Other (income) expense, net	(91)	355	(306)	35	(6)	328	(208)	(569)	(349)	(798)	(235)	(387)
(Loss) income before income taxes	(4,486)	2,053	956	2,168	690	1,649	2,429	3,641	2,078	9,796	2,580	(10,254)
Income tax (benefit) expense	(315)	438	(297)	385	211	334	468	589	(105)	1,286	559	242
Net (loss) income	(4,170)	1,614	1,253	1,783	480	1,315	1,960	3,052	2,183	8,510	2,021	(10,496)
Basic (loss) earnings per share	\$ (3.34)	\$ 1.29	\$ 1.00	\$ 1.43	\$ 0.38	\$ 1.06	\$ 1.57	\$ 2.46	\$ 1.76	\$ 6.84	\$ 1.63	\$ (8.45)
Diluted (loss) earnings per share	\$ (3.34)	\$ 1.29	\$ 1.00	\$ 1.42	\$ 0.38	\$ 1.04	\$ 1.56	\$ 2.43	\$ 1.74	\$ 6.78	\$ 1.61	\$ (8.45)
Shares used in basic (loss) earnings per share calculation	1,247	1,247	1,247	1,248	1,247	1,246	1,245	1,243	1,242	1,244	1,242	1,243
Shares used in diluted (loss) earnings per share calculation	1,247	1,251	1,254	1,259	1,255	1,259	1,255	1,254	1,253	1,255	1,254	1,243
Supplemental Information:												
Cash dividends declared per share	\$ 0.77	\$ 0.77	\$ 0.77	\$ 0.77	\$ 3.08	\$ 0.79	\$ 0.79	\$ 0.79	\$ 0.79	\$ 3.16	\$ 0.82	\$ 0.82
Product gross margin	76.6 %	77.7 %	79.1 %	79.0 %	78.2 %	76.7 %	78.7 %	78.6 %	79.5 %	78.4 %	79.2 %	79.3 %
Research and development expenses as a % of revenues	22.7 %	19.4 %	18.5 %	21.7 %	20.5 %	20.7 %	21.1 %	17.3 %	20.0 %	19.7 %	19.7 %	22.6 %
Selling, general and administrative expenses as a % of revenues	20.6 %	19.8 %	19.0 %	25.2 %	21.2 %	18.9 %	19.3 %	17.5 %	22.6 %	19.6 %	20.9 %	24.6 %
Operating margin	(64.6)%	38.0 %	11.8 %	32.4 %	5.8 %	33.6 %	34.9 %	42.8 %	25.0 %	34.0 %	37.2 %	(133.2)%
Effective tax rate	7.0 %	21.4 %	(31.1)%	17.8 %	30.5 %	20.2 %	19.3 %	16.2 %	(5.0)%	13.1 %	21.7 %	(2.4)%

Certain amounts and percentages may not sum or recalculate due to rounding.



SELECTED CASH FLOW INFORMATION
(unaudited)

	2024					2025					2026	
(in millions)	Q1	Q2	Q3	Q4	FY24	Q1	Q2	Q3	Q4	FY25	Q1	Q2
Net cash provided by operating activities	\$ 2,219	\$ 1,325	\$ 4,309	\$ 2,975	\$ 10,828	\$ 1,757	\$ 827	\$ 4,109	\$ 3,326	\$ 10,019	\$ 2,544	\$ 3,573
Net cash (used in) provided by investing activities	(2,207)	(307)	(710)	(225)	(3,449)	(415)	(2,116)	(427)	(1,835)	(4,793)	1,770	(10,347)
Net cash (used in) provided by financing activities	(1,361)	(2,953)	(1,379)	2,260	(3,433)	(3,426)	(1,566)	(1,490)	(1,263)	(7,745)	(4,239)	2,344
Effect of exchange rate changes on cash and cash equivalents	(18)	(11)	44	(55)	(40)	19	73	(5)	5	92	(11)	(19)
Net change in cash and cash equivalents	(1,367)	(1,947)	2,265	4,954	3,906	(2,065)	(2,782)	2,187	233	(2,428)	65	(4,450)
Cash and cash equivalents, beginning of period	6,085	4,718	2,772	5,037	6,085	9,991	7,926	5,144	7,330	9,991	7,564	7,628
Cash and cash equivalents, end of period	<u>\$ 4,718</u>	<u>\$ 2,772</u>	<u>\$ 5,037</u>	<u>\$ 9,991</u>	<u>\$ 9,991</u>	<u>\$ 7,926</u>	<u>\$ 5,144</u>	<u>\$ 7,330</u>	<u>\$ 7,564</u>	<u>\$ 7,564</u>	<u>\$ 7,628</u>	<u>\$ 3,179</u>

	2024					2025					2026	
(in millions)	Q1	Q2	Q3	Q4	FY24	Q1	Q2	Q3	Q4	FY25	Q1	Q2
Net cash provided by operating activities	\$ 2,219	\$ 1,325	\$ 4,309	\$ 2,975	\$ 10,828	\$ 1,757	\$ 827	\$ 4,109	\$ 3,326	\$ 10,019	\$ 2,544	\$ 3,573
Purchases of property, plant and equipment	(105)	(130)	(140)	(147)	(523)	(104)	(107)	(147)	(205)	(563)	(117)	(140)
Free cash flow ⁽¹⁾	<u>\$ 2,114</u>	<u>\$ 1,195</u>	<u>\$ 4,169</u>	<u>\$ 2,828</u>	<u>\$ 10,305</u>	<u>\$ 1,653</u>	<u>\$ 720</u>	<u>\$ 3,962</u>	<u>\$ 3,121</u>	<u>\$ 9,456</u>	<u>\$ 2,427</u>	<u>\$ 3,432</u>

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section of our Press Release, issued by Gilead Sciences, Inc. on August 4, 2026 on Form 8-K, which is available on <http://investors.gilead.com>.



NON-GAAP FINANCIAL INFORMATION⁽¹⁾
(unaudited)

(in millions, except percentages and per share amounts)	2024					2025					2026	
	Q1	Q2	Q3	Q4	FY24	Q1	Q2	Q3	Q4	FY25	Q1	Q2
Non-GAAP:												
Cost of goods sold	\$ 974	\$ 965	\$ 995	\$ 1,002	\$ 3,936	\$ 961	\$ 922	\$ 992	\$ 1,044	\$ 3,919	\$ 869	\$ 999
Research and development expenses	\$ 1,403	\$ 1,335	\$ 1,382	\$ 1,612	\$ 5,732	\$ 1,338	\$ 1,450	\$ 1,334	\$ 1,565	\$ 5,687	\$ 1,355	\$ 1,429
Acquired in-process research and development expenses	\$ 4,131	\$ 38	\$ 505	\$ (11)	\$ 4,663	\$ 253	\$ 61	\$ 170	\$ 539	\$ 1,024	\$ 107	\$ 11,183
Selling, general and administrative expenses	\$ 1,295	\$ 1,351	\$ 1,405	\$ 1,852	\$ 5,903	\$ 1,222	\$ 1,358	\$ 1,351	\$ 1,688	\$ 5,619	\$ 1,363	\$ 1,521
Other (income) expense, net	\$ (104)	\$ (37)	\$ (48)	\$ (91)	\$ (279)	\$ (98)	\$ (66)	\$ (87)	\$ (97)	\$ (348)	\$ (92)	\$ (44)
Diluted (loss) earnings per share	\$ (1.32)	\$ 2.01	\$ 2.02	\$ 1.90	\$ 4.62	\$ 1.81	\$ 2.01	\$ 2.47	\$ 1.86	\$ 8.15	\$ 2.03	\$ (6.75)
Shares used in non-GAAP diluted (loss) earnings per share	1,247	1,251	1,254	1,259	1,255	1,259	1,255	1,254	1,253	1,255	1,254	1,243
Product gross margin	85.4 %	86.0 %	86.8 %	86.7 %	86.2 %	85.5 %	86.9 %	86.5 %	86.8 %	86.4 %	87.5 %	86.9 %
Research and development expenses as a % of revenues	21.0 %	19.2 %	18.3 %	21.3 %	19.9 %	20.1 %	20.5 %	17.2 %	19.7 %	19.3 %	19.5 %	18.3 %
Selling, general and administrative expenses as a % of revenues	19.4 %	19.4 %	18.6 %	24.5 %	20.5 %	18.3 %	19.2 %	17.4 %	21.3 %	19.1 %	19.6 %	19.5 %
Operating margin	(16.7)%	47.0 %	43.2 %	41.1 %	29.6 %	43.4 %	46.5 %	50.5 %	39.0 %	44.8 %	46.9 %	(93.9)%
Effective tax rate	(29.8)%	17.8 %	17.5 %	19.2 %	25.9 %	16.3 %	18.8 %	17.5 %	20.5 %	18.3 %	18.3 %	(11.4)%

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ Please refer to our disclosures in the Non-GAAP Financial Information section of our Press Release, issued by Gilead Sciences, Inc. on August 4, 2026 on Form 8-K, which is available on <http://investors.gilead.com>. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 5-7.



RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(unaudited)

	2024					2025					2026	
(in millions, except percentages and per share amounts)	Q1	Q2	Q3	Q4	FY24	Q1	Q2	Q3	Q4	FY25	Q1	Q2
Cost of goods sold reconciliation:												
GAAP cost of goods sold	\$ 1,552	\$ 1,544	\$ 1,574	\$ 1,581	\$ 6,251	\$ 1,540	\$ 1,501	\$ 1,569	\$ 1,623	\$ 6,234	\$ 1,445	\$ 1,579
Acquisition-related – amortization ⁽¹⁾	(579)	(579)	(579)	(579)	(2,316)	(579)	(579)	(577)	(576)	(2,310)	(576)	(579)
Restructuring	—	—	—	—	—	—	—	—	(4)	(4)	(1)	—
Non-GAAP cost of goods sold	<u>\$ 974</u>	<u>\$ 965</u>	<u>\$ 995</u>	<u>\$ 1,002</u>	<u>\$ 3,936</u>	<u>\$ 961</u>	<u>\$ 922</u>	<u>\$ 992</u>	<u>\$ 1,044</u>	<u>\$ 3,919</u>	<u>\$ 869</u>	<u>\$ 999</u>
Product gross margin reconciliation:												
GAAP product gross margin	76.6 %	77.7 %	79.1 %	79.0 %	78.2 %	76.7 %	78.7 %	78.6 %	79.5 %	78.4 %	79.2 %	79.3 %
Acquisition-related – amortization ⁽¹⁾	8.7 %	8.4 %	7.7 %	7.7 %	8.1 %	8.8 %	8.2 %	7.9 %	7.3 %	8.0 %	8.3 %	7.6 %
Restructuring	— %	— %	— %	— %	— %	— %	— %	— %	— %	— %	— %	— %
Non-GAAP product gross margin	<u>85.4 %</u>	<u>86.0 %</u>	<u>86.8 %</u>	<u>86.7 %</u>	<u>86.2 %</u>	<u>85.5 %</u>	<u>86.9 %</u>	<u>86.5 %</u>	<u>86.8 %</u>	<u>86.4 %</u>	<u>87.5 %</u>	<u>86.9 %</u>
Research and development expenses reconciliation:												
GAAP research and development expenses	\$ 1,520	\$ 1,351	\$ 1,395	\$ 1,641	\$ 5,907	\$ 1,379	\$ 1,491	\$ 1,346	\$ 1,584	\$ 5,799	\$ 1,372	\$ 1,764
Acquisition-related – other costs ⁽²⁾	(66)	(3)	(9)	—	(78)	(2)	(35)	(4)	(3)	(43)	(3)	(333)
Restructuring	(50)	(13)	(5)	(30)	(98)	(38)	(6)	(8)	(16)	(69)	(14)	(2)
Non-GAAP research and development expenses	<u>\$ 1,403</u>	<u>\$ 1,335</u>	<u>\$ 1,382</u>	<u>\$ 1,612</u>	<u>\$ 5,732</u>	<u>\$ 1,338</u>	<u>\$ 1,450</u>	<u>\$ 1,334</u>	<u>\$ 1,565</u>	<u>\$ 5,687</u>	<u>\$ 1,355</u>	<u>\$ 1,429</u>
IPR&D impairment reconciliation:												
GAAP IPR&D impairment	\$ 2,430	\$ —	\$ 1,750	\$ —	\$ 4,180	\$ —	\$ 190	\$ —	\$ 400	\$ 590	\$ —	\$ 1,750
IPR&D impairment	(2,430)	—	(1,750)	—	(4,180)	—	(190)	—	(400)	(590)	—	(1,750)
Non-GAAP IPR&D impairment	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>
Selling, general and administrative expenses reconciliation:												
GAAP selling, general and administrative expenses	\$ 1,375	\$ 1,377	\$ 1,433	\$ 1,906	\$ 6,091	\$ 1,258	\$ 1,365	\$ 1,357	\$ 1,794	\$ 5,774	\$ 1,451	\$ 1,921
Acquisition-related – other costs ⁽²⁾	(67)	(17)	(5)	(8)	(97)	—	—	—	—	—	—	(385)
Restructuring	(13)	(8)	(23)	(46)	(91)	(36)	(7)	(5)	(17)	(65)	(25)	(15)
Other ⁽³⁾	—	—	—	—	—	—	—	—	(89)	(89)	(63)	—
Non-GAAP selling, general and administrative expenses	<u>\$ 1,295</u>	<u>\$ 1,351</u>	<u>\$ 1,405</u>	<u>\$ 1,852</u>	<u>\$ 5,903</u>	<u>\$ 1,222</u>	<u>\$ 1,358</u>	<u>\$ 1,351</u>	<u>\$ 1,688</u>	<u>\$ 5,619</u>	<u>\$ 1,363</u>	<u>\$ 1,521</u>
Operating (loss) income reconciliation:												
GAAP operating (loss) income	\$ (4,322)	\$ 2,644	\$ 888	\$ 2,451	\$ 1,662	\$ 2,237	\$ 2,474	\$ 3,327	\$ 1,984	\$ 10,022	\$ 2,586	\$ (10,394)
Acquisition-related – amortization ⁽¹⁾	579	579	579	579	2,316	579	579	577	576	2,310	576	579
Acquisition-related – other costs ⁽²⁾	133	21	13	8	174	2	35	4	3	43	3	718
Restructuring	63	21	28	76	188	74	13	14	37	138	40	17
IPR&D impairment	2,430	—	1,750	—	4,180	—	190	—	400	590	—	1,750
Other ⁽³⁾	—	—	—	—	—	—	—	—	89	89	63	—
Non-GAAP operating (loss) income	<u>\$ (1,117)</u>	<u>\$ 3,265</u>	<u>\$ 3,258</u>	<u>\$ 3,114</u>	<u>\$ 8,520</u>	<u>\$ 2,893</u>	<u>\$ 3,290</u>	<u>\$ 3,921</u>	<u>\$ 3,089</u>	<u>\$ 13,193</u>	<u>\$ 3,267</u>	<u>\$ (7,329)</u>
Operating margin reconciliation:												
GAAP operating margin	(64.6) %	38.0 %	11.8 %	32.4 %	5.8 %	33.6 %	34.9 %	42.8 %	25.0 %	34.0 %	37.2 %	(133.2) %
Acquisition-related – amortization ⁽¹⁾	8.7 %	8.3 %	7.7 %	7.6 %	8.1 %	8.7 %	8.2 %	7.4 %	7.3 %	7.8 %	8.3 %	7.4 %
Acquisition-related – other costs ⁽²⁾	2.0 %	0.3 %	0.2 %	0.1 %	0.6 %	— %	0.5 %	— %	— %	0.1 %	— %	9.2 %
Restructuring	0.9 %	0.3 %	0.4 %	1.0 %	0.7 %	1.1 %	0.2 %	0.2 %	0.5 %	0.5 %	0.6 %	0.2 %
IPR&D impairment	36.3 %	— %	23.2 %	— %	14.5 %	— %	2.7 %	— %	5.0 %	2.0 %	— %	22.4 %
Other ⁽³⁾	— %	— %	— %	— %	— %	— %	— %	— %	1.1 %	0.3 %	0.9 %	— %
Non-GAAP operating margin	<u>(16.7) %</u>	<u>47.0 %</u>	<u>43.2 %</u>	<u>41.1 %</u>	<u>29.6 %</u>	<u>43.4 %</u>	<u>46.5 %</u>	<u>50.5 %</u>	<u>39.0 %</u>	<u>44.8 %</u>	<u>46.9 %</u>	<u>(93.9) %</u>
Other (income) expense, net reconciliation:												
GAAP other (income) expense, net	\$ (91)	\$ 355	\$ (306)	\$ 35	\$ (6)	\$ 328	\$ (208)	\$ (569)	\$ (349)	\$ (798)	\$ (235)	\$ (387)
(Loss) gain from equity securities, net	(14)	(392)	258	(126)	(274)	(426)	142	483	252	451	142	343
Non-GAAP other (income) expense, net	<u>\$ (104)</u>	<u>\$ (37)</u>	<u>\$ (48)</u>	<u>\$ (91)</u>	<u>\$ (279)</u>	<u>\$ (98)</u>	<u>\$ (66)</u>	<u>\$ (87)</u>	<u>\$ (97)</u>	<u>\$ (348)</u>	<u>\$ (92)</u>	<u>\$ (44)</u>



RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)
(unaudited)

	2024					2025					2026	
(in millions, except percentages and per share amounts)	Q1	Q2	Q3	Q4	FY24	Q1	Q2	Q3	Q4	FY25	Q1	Q2
(Loss) income before income taxes reconciliation:												
GAAP (loss) income before income taxes	\$ (4,486)	\$ 2,053	\$ 956	\$ 2,168	\$ 690	\$ 1,649	\$ 2,429	\$ 3,641	\$ 2,078	\$ 9,796	\$ 2,580	\$(10,254)
Acquisition-related – amortization ⁽¹⁾	579	579	579	579	2,316	579	579	577	576	2,310	576	579
Acquisition-related – other costs ⁽²⁾	133	21	13	8	174	2	35	4	3	43	3	718
Restructuring	63	21	28	76	188	74	13	14	37	138	40	17
IPR&D impairment	2,430	—	1,750	—	4,180	—	190	—	400	590	—	1,750
Loss (gain) from equity securities, net	14	392	(258)	126	274	426	(142)	(483)	(252)	(451)	(142)	(343)
Other ⁽³⁾	—	—	—	—	—	—	—	—	89	89	63	—
Non-GAAP (loss) income before income taxes:	<u>\$ (1,267)</u>	<u>\$ 3,065</u>	<u>\$ 3,068</u>	<u>\$ 2,956</u>	<u>\$ 7,822</u>	<u>\$ 2,731</u>	<u>\$ 3,103</u>	<u>\$ 3,752</u>	<u>\$ 2,930</u>	<u>\$ 12,517</u>	<u>\$ 3,119</u>	<u>\$ (7,531)</u>
Income tax expense reconciliation:												
GAAP income tax (benefit) expense	\$ (315)	\$ 438	\$ (297)	\$ 385	\$ 211	\$ 334	\$ 468	\$ 589	\$ (105)	\$ 1,286	\$ 559	\$ 242
Income tax effect of non-GAAP adjustments:												
Acquisition-related – amortization ⁽¹⁾	121	121	121	121	484	120	120	120	118	478	118	119
Acquisition-related – other costs ⁽²⁾	30	7	2	2	41	—	—	—	—	—	—	79
Restructuring	10	7	4	16	37	14	2	3	7	25	6	3
IPR&D impairment	611	—	440	—	1,051	—	51	—	87	137	—	415
(Gain) loss from equity securities, net	(39)	33	(46)	13	(39)	20	(11)	(43)	14	(20)	(66)	(42)
Discrete and related tax charges ⁽⁴⁾	(39)	(60)	314	29	243	(42)	(48)	(11)	454	353	(46)	44
Other ⁽³⁾	—	—	—	—	—	—	—	—	27	27	—	—
Non-GAAP income tax expense	<u>\$ 379</u>	<u>\$ 546</u>	<u>\$ 538</u>	<u>\$ 566</u>	<u>\$ 2,028</u>	<u>\$ 446</u>	<u>\$ 583</u>	<u>\$ 657</u>	<u>\$ 601</u>	<u>\$ 2,287</u>	<u>\$ 570</u>	<u>\$ 860</u>
Effective tax rate reconciliation:												
GAAP effective tax rate	7.0 %	21.4 %	(31.1)%	17.8 %	30.5 %	20.2 %	19.3 %	16.2 %	(5.0)%	13.1 %	21.7 %	(2.4)%
Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments ⁽⁴⁾	(36.8)%	(3.5)%	48.6 %	1.4 %	(4.6)%	(3.9)%	(0.5)%	1.3 %	25.6 %	5.1 %	(3.4)%	(9.1)%
Non-GAAP effective tax rate	<u>(29.8)%</u>	<u>17.8 %</u>	<u>17.5 %</u>	<u>19.2 %</u>	<u>25.9 %</u>	<u>16.3 %</u>	<u>18.8 %</u>	<u>17.5 %</u>	<u>20.5 %</u>	<u>18.3 %</u>	<u>18.3 %</u>	<u>(11.4)%</u>
Net (loss) income reconciliation:												
GAAP net (loss) income	\$ (4,170)	\$ 1,614	\$ 1,253	\$ 1,783	\$ 480	\$ 1,315	\$ 1,960	\$ 3,052	\$ 2,183	\$ 8,510	\$ 2,021	\$(10,496)
Acquisition-related – amortization ⁽¹⁾	458	458	458	458	1,832	459	459	457	458	1,832	458	461
Acquisition-related – other costs ⁽²⁾	103	14	11	6	134	2	35	4	3	43	3	640
Restructuring	54	14	24	59	151	61	11	11	30	113	34	14
IPR&D impairment	1,819	—	1,310	—	3,129	—	139	—	313	453	—	1,335
Loss (gain) from equity securities, net	53	359	(212)	113	313	406	(131)	(440)	(266)	(431)	(77)	(301)
Discrete and related tax charges ⁽⁴⁾	39	60	(314)	(29)	(243)	42	48	11	(454)	(353)	46	(44)
Other ⁽³⁾	—	—	—	—	—	—	—	—	63	63	63	—
Non-GAAP net (loss) income	<u>\$ (1,644)</u>	<u>\$ 2,519</u>	<u>\$ 2,531</u>	<u>\$ 2,390</u>	<u>\$ 5,795</u>	<u>\$ 2,285</u>	<u>\$ 2,521</u>	<u>\$ 3,095</u>	<u>\$ 2,329</u>	<u>\$ 10,230</u>	<u>\$ 2,549</u>	<u>\$ (8,391)</u>
Diluted (loss) earnings per share reconciliation:												
GAAP diluted (loss) earnings per share	\$ (3.34)	\$ 1.29	\$ 1.00	\$ 1.42	\$ 0.38	\$ 1.04	\$ 1.56	\$ 2.43	\$ 1.74	\$ 6.78	\$ 1.61	\$ (8.45)
Acquisition-related – amortization ⁽¹⁾	0.37	0.37	0.37	0.36	1.46	0.36	0.37	0.36	0.37	1.46	0.37	0.37
Acquisition-related – other costs ⁽²⁾	0.08	0.01	0.01	—	0.11	—	0.03	—	—	0.03	—	0.51
Restructuring	0.04	0.01	0.02	0.05	0.12	0.05	0.01	0.01	0.02	0.09	0.03	0.01
IPR&D impairment	1.46	—	1.04	—	2.49	—	0.11	—	0.25	0.36	—	1.07
Loss (gain) from equity securities, net	0.04	0.29	(0.17)	0.09	0.25	0.32	(0.10)	(0.35)	(0.21)	(0.34)	(0.06)	(0.24)
Discrete and related tax charges ⁽⁴⁾	0.03	0.05	(0.25)	(0.02)	(0.19)	0.03	0.04	0.01	(0.36)	(0.28)	0.04	(0.04)
Other ⁽³⁾	—	—	—	—	—	—	—	—	0.05	0.05	0.05	—
Non-GAAP diluted (loss) earnings per share	<u>\$ (1.32)</u>	<u>\$ 2.01</u>	<u>\$ 2.02</u>	<u>\$ 1.90</u>	<u>\$ 4.62</u>	<u>\$ 1.81</u>	<u>\$ 2.01</u>	<u>\$ 2.47</u>	<u>\$ 1.86</u>	<u>\$ 8.15</u>	<u>\$ 2.03</u>	<u>\$ (6.75)</u>



RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)
(unaudited)

(in millions, except percentages and per share amounts)	2024					2025					2026	
	Q1	Q2	Q3	Q4	FY24	Q1	Q2	Q3	Q4	FY25	Q1	Q2
Non-GAAP adjustment summary:												
Cost of goods sold adjustments	\$ 579	\$ 579	\$ 579	\$ 579	\$ 2,315	\$ 579	\$ 579	\$ 577	\$ 579	\$ 2,314	\$ 576	\$ 579
Research and development expenses adjustments	117	16	13	29	176	40	41	12	19	112	17	335
IPR&D impairment adjustments	2,430	—	1,750	—	4,180	—	190	—	400	590	—	1,750
Selling, general and administrative expenses adjustments	80	26	28	54	188	36	7	5	106	155	88	400
Total non-GAAP adjustments to costs and expenses	3,205	620	2,370	663	6,858	656	817	594	1,104	3,171	681	3,065
Other (income) expense, net, adjustments	14	392	(258)	126	274	426	(142)	(483)	(252)	(451)	(142)	(343)
Total non-GAAP adjustments before income taxes	3,219	1,012	2,113	789	7,132	1,082	675	112	852	2,720	539	2,722
Income tax effect of non-GAAP adjustments above	(732)	(168)	(521)	(152)	(1,574)	(154)	(162)	(79)	(252)	(647)	(58)	(574)
Discrete and related tax charges ⁽⁴⁾	39	60	(314)	(29)	(243)	42	48	11	(454)	(353)	46	(44)
Total non-GAAP adjustments after tax	\$ 2,526	\$ 905	\$ 1,278	\$ 607	\$ 5,315	\$ 970	\$ 560	\$ 43	\$ 146	\$ 1,719	\$ 528	\$ 2,105

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ Relates to amortization of acquired intangibles.

⁽²⁾ Relates primarily to integration expenses, contingent consideration fair value adjustments and other expenses associated with Gilead's recent acquisitions.

⁽³⁾ The adjustments in Selling, general and administrative expenses relate to donations of equity securities to the Gilead Foundation, a California nonprofit organization, during the fourth quarter of 2025 and first quarter of 2026.

⁽⁴⁾ Represents discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and in-process research and development, acquisition-related adjustments, transfers of intangible assets from a foreign subsidiary to Ireland and the United States, and legal entity restructurings.



TOTAL REVENUE SUMMARY
(unaudited)

(in millions)	2024					2025					2026	
	Q1	Q2	Q3	Q4	FY24	Q1	Q2	Q3	Q4	FY25	Q1	Q2
Product sales ⁽¹⁾ :												
HIV	\$ 4,342	\$ 4,745	\$ 5,073	\$ 5,452	\$ 19,612	\$ 4,587	\$ 5,088	\$ 5,277	\$ 5,801	\$ 20,752	\$ 5,030	\$ 5,693
Liver Disease	737	832	733	719	3,021	758	795	819	844	3,217	767	877
Oncology	789	841	816	843	3,289	757	849	788	842	3,236	810	873
Other	224	280	201	184	889	209	202	184	205	799	196	161
Total product sales excluding Veklury	6,092	6,698	6,823	7,198	26,811	6,311	6,934	7,068	7,691	28,004	6,802	7,604
Veklury	555	214	692	337	1,799	302	121	277	212	911	144	23
Total product sales	6,647	6,912	7,515	7,536	28,610	6,613	7,054	7,345	7,903	28,915	6,946	7,627
Royalty, contract and other revenues	39	41	30	33	144	54	27	424	22	527	14	176
Total revenues	<u>\$ 6,686</u>	<u>\$ 6,954</u>	<u>\$ 7,545</u>	<u>\$ 7,569</u>	<u>\$ 28,754</u>	<u>\$ 6,667</u>	<u>\$ 7,082</u>	<u>\$ 7,769</u>	<u>\$ 7,925</u>	<u>\$ 29,443</u>	<u>\$ 6,960</u>	<u>\$ 7,803</u>

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ See Product Sales Summary on pages 9-11 for more details.



PRODUCT SALES SUMMARY
(unaudited)

(in millions)		2024					2025					2026	
		Q1	Q2	Q3	Q4	FY24	Q1	Q2	Q3	Q4	FY25	Q1	Q2
HIV													
Biktarvy	U.S.	\$ 2,315	\$ 2,585	\$ 2,826	\$ 3,129	\$ 10,855	\$ 2,474	\$ 2,799	\$ 2,940	\$ 3,255	\$ 11,467	\$ 2,573	\$ 2,981
	Europe	365	370	375	400	1,509	375	429	427	446	1,676	437	468
	Rest of World	265	277	272	246	1,060	301	302	320	268	1,190	352	323
		2,946	3,232	3,472	3,774	13,423	3,150	3,530	3,686	3,968	14,334	3,361	3,772
Descovy	U.S.	371	434	534	563	1,902	538	601	652	768	2,559	761	921
	Europe	26	25	24	25	100	21	24	23	26	93	23	23
	Rest of World	29	26	28	28	110	27	28	25	25	105	23	23
		426	485	586	616	2,113	586	653	701	819	2,758	807	967
Genvoya	U.S.	332	372	384	410	1,498	305	322	323	331	1,281	215	236
	Europe	49	45	44	42	180	40	40	34	34	148	33	37
	Rest of World	21	23	21	18	84	19	16	19	15	69	16	16
		403	440	449	470	1,762	364	377	377	380	1,498	264	289
Odefsey	U.S.	223	233	248	252	957	215	221	206	238	881	153	171
	Europe	76	72	69	74	290	57	66	61	62	246	59	58
	Rest of World	11	10	9	11	41	10	11	10	10	40	9	10
		310	315	326	336	1,288	281	298	277	310	1,167	221	239
Symtuza – Revenue share ⁽¹⁾	U.S.	104	131	103	112	450	82	88	95	98	363	107	105
	Europe	33	34	33	30	130	29	33	26	32	120	28	30
	Rest of World	3	3	3	3	12	3	3	3	3	12	3	3
		141	168	139	144	592	114	124	124	134	495	138	138
Yeztugo	U.S.	—	—	—	—	—	—	15	39	96	150	158	223
	Europe	—	—	—	—	—	—	—	—	—	—	—	—
	Rest of World	—	—	—	—	—	—	—	—	—	—	7	9
		—	—	—	—	—	—	15	39	96	150	166	232
Other HIV ⁽²⁾	U.S.	60	65	65	67	257	50	50	43	58	202	36	23
	Europe	45	25	26	33	129	31	33	22	24	109	27	24
	Rest of World	12	15	9	11	48	10	9	9	12	40	9	10
		117	105	100	111	434	91	92	73	94	350	73	56
Total HIV	U.S.	3,405	3,821	4,161	4,532	15,918	3,664	4,096	4,299	4,845	16,904	4,004	4,659
	Europe	596	571	570	603	2,339	553	624	592	624	2,392	607	640
	Rest of World	342	353	342	317	1,355	370	368	386	332	1,456	419	393
		4,342	4,745	5,073	5,452	19,612	4,587	5,088	5,277	5,801	20,752	5,030	5,693

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ Represents Gilead's revenue from cobicistat ("C"), emtricitabine ("FTC") and tenofovir alafenamide ("TAF") in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

⁽²⁾ Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada and Tybost.



PRODUCT SALES SUMMARY (Continued)

(unaudited)

(in millions)		2024					2025					2026	
		Q1	Q2	Q3	Q4	FY24	Q1	Q2	Q3	Q4	FY25	Q1	Q2
Liver Disease													
Livdelzi	U.S.	—	—	1	30	31	40	74	93	135	342	115	147
	Europe	—	—	—	—	—	—	4	11	15	31	18	20
	Rest of World	—	—	—	—	—	—	—	—	—	—	—	—
		—	—	1	30	31	40	78	105	150	373	133	167
Sofosbuvir/Velpatasvir ⁽³⁾	U.S.	248	267	222	185	922	166	184	146	140	636	141	142
	Europe	79	84	67	69	299	80	81	65	66	292	60	81
	Rest of World	78	126	96	75	374	99	76	97	71	344	82	80
		405	476	385	330	1,596	346	342	309	276	1,272	283	303
Vemlidy	U.S.	95	117	126	148	486	100	122	136	149	507	91	124
	Europe	11	11	11	11	44	12	13	12	12	49	13	13
	Rest of World	119	115	95	100	428	140	117	132	125	514	132	152
		225	243	232	260	959	252	252	280	287	1,070	237	289
Other Liver Disease ⁽⁴⁾	U.S.	42	47	44	27	161	28	33	39	34	134	15	20
	Europe	47	47	54	54	202	76	72	70	82	299	78	79
	Rest of World	19	19	17	18	73	17	19	17	16	69	21	19
		107	113	115	100	435	121	123	126	131	501	114	118
Total Liver Disease	U.S.	385	431	393	391	1,601	335	413	414	457	1,619	362	433
	Europe	137	142	132	134	545	168	170	158	174	671	170	193
	Rest of World	215	259	207	194	876	256	211	247	212	927	235	251
		737	832	733	719	3,021	758	795	819	844	3,217	767	877
Veklury													
Veklury	U.S.	315	76	393	108	892	199	51	140	80	470	112	14
	Europe	70	53	81	80	284	22	19	43	67	151	14	2
	Rest of World	169	85	219	150	623	82	50	93	65	290	18	7
		555	214	692	337	1,799	302	121	277	212	911	144	23
Oncology													
Cell Therapy													
Tecartus	U.S.	55	63	63	53	234	40	41	40	32	153	30	29
	Europe	36	37	29	36	138	31	41	35	51	158	37	34
	Rest of World	8	7	6	10	31	8	9	8	7	32	8	8
		100	107	98	98	403	78	92	83	90	344	75	70
Yescarta	U.S.	170	186	145	161	662	160	162	123	151	595	120	132
	Europe	158	169	182	156	666	149	154	151	143	598	146	139
	Rest of World	52	58	60	72	242	77	77	75	74	303	67	75
		380	414	387	390	1,570	386	393	349	368	1,495	332	346
Total Cell Therapy	U.S.	225	250	208	213	896	200	203	163	183	748	150	161
	Europe	195	206	211	193	804	180	196	186	193	755	183	173
	Rest of World	60	66	66	82	274	84	86	83	82	335	74	83
		480	521	485	488	1,973	464	485	432	458	1,839	407	417
Trodelvy													
Trodelvy	U.S.	206	224	226	247	902	181	224	221	251	877	253	307
	Europe	68	69	80	77	294	75	96	89	88	347	95	92
	Rest of World	36	26	26	31	119	37	44	47	45	173	54	57
		309	320	332	355	1,315	293	364	357	384	1,397	402	457
Total Oncology	U.S.	431	474	433	461	1,798	381	427	384	434	1,626	403	468
	Europe	262	275	291	269	1,098	255	291	275	281	1,102	278	265
	Rest of World	96	92	92	113	393	121	131	129	127	508	129	140
		789	841	816	843	3,289	757	849	788	842	3,236	810	873

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽³⁾ Includes Epclusa and the authorized generic version of Epclusa sold by Gilead's separate subsidiary, Asegua Therapeutics LLC ("Asegua").

⁽⁴⁾ Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Sovaldi, Viread and Vosevi.

Questions? Contact Investor_Relations@gilead.com



PRODUCT SALES SUMMARY (Continued)
(unaudited)

(in millions)		2024					2025					2026	
		Q1	Q2	Q3	Q4	FY24	Q1	Q2	Q3	Q4	FY25	Q1	Q2
Other													
AmBisome	U.S.	14	17	6	7	44	5	7	2	5	20	7	4
	Europe	70	69	71	66	276	67	65	69	66	267	59	47
	Rest of World	60	65	52	36	212	66	56	52	47	221	72	59
		144	151	130	109	533	139	129	123	118	509	138	110
Other ⁽⁵⁾	U.S.	59	98	47	51	255	47	44	34	52	177	39	22
	Europe	9	8	8	8	34	9	8	7	9	32	8	8
	Rest of World	12	24	16	16	68	14	21	20	26	81	11	21
		80	130	71	76	356	70	73	61	87	290	58	51
Total Other	U.S.	73	115	53	59	299	52	52	36	57	197	46	26
	Europe	79	77	80	74	310	76	73	76	75	300	67	55
	Rest of World	71	88	68	52	280	81	77	72	72	302	83	80
		224	280	201	184	889	209	202	184	205	799	196	161
Total product sales	U.S.	4,609	4,916	5,433	5,550	20,508	4,631	5,038	5,274	5,873	20,816	4,926	5,601
	Europe	1,144	1,118	1,154	1,160	4,576	1,073	1,178	1,144	1,221	4,617	1,137	1,155
	Rest of World	894	878	928	826	3,526	909	838	928	808	3,483	883	872
		<u>\$ 6,647</u>	<u>\$ 6,912</u>	<u>\$ 7,515</u>	<u>\$ 7,536</u>	<u>\$ 28,610</u>	<u>\$ 6,613</u>	<u>\$ 7,054</u>	<u>\$ 7,345</u>	<u>\$ 7,903</u>	<u>\$ 28,915</u>	<u>\$ 6,946</u>	<u>\$ 7,627</u>

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽⁵⁾ Includes Cayston, Jyseleca, Letairis and Zydelig.